{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:18Z","timestamp":1790286918015,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Lichenoid drug reaction is a common adverse reaction in patients taking immune-modulatory agents such as antiprogramed cell death (PD-1) and cytotoxic T lymphocyte antigen\u20134 agents. The authors describe the clinical and histologic features of lichenoid drug reaction in 20 biopsies from 15 patients on anti\u2013PD-1 agents and 9 biopsies from 7 patients on anti\u2013PD-1 plus ipilimumab therapy. Clinically, all except 2 patients presented with discrete, violaceous exanthematous papules to plaques. The lichenoid inflammation in the majority (18 of 29 biopsies) was florid although histology was quite heterogeneous. Nevertheless, there was frequent involvement of the superficial follicular epithelium and acrosyringium, and also a propensity to blister that occurred in approximately 20% of the biopsies. Occasional patients had disease closely resembling lichen planus, although all of these biopsies had some atypical features for lichen planus such as parakeratosis. Dermal eosinophils were common particularly in those with mild inflammation. The lichenoid reaction was responsive to topical steroid or oral systemic treatment in general, and the anti\u2013PD-1 agent had to be ceased in only one patient.<\/jats:p>","DOI":"10.1097\/dad.0000000000000587","type":"journal-article","created":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T15:03:24Z","timestamp":1483196604000},"page":"23-27","source":"Crossref","is-referenced-by-count":29,"title":["Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death\u20131 (anti\u2013PD-1) Therapy With or Without Ipilimumab"],"prefix":"10.1097","volume":"39","author":[{"given":"Shaun","family":"Chou","sequence":"first","affiliation":[{"name":"Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley Ji Eun","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital, Sydney, Australia; and"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Carlos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital, Sydney, Australia; and"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepal","family":"Wakade","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital, Sydney, Australia; and"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital, Sydney, Australia; and"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/PPO.0000000000000055","article-title":"Subverting the B7-H1\/PD-1 pathway in advanced melanoma and kidney cancer","volume":"20","author":"Harshman","year":"2014","journal-title":"Cancer J."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00403-014-1457-7","article-title":"Targeting the PD-1 pathway: a promising future for the treatment of melanoma","volume":"306","author":"Mamalis","year":"2014","journal-title":"Arch Dermatol Res."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity and immune correlated of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Niovlumab and ipilimumab versus ipililumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"JAAD."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-0960.2012.00921.x","article-title":"Paraneoplastic pemphigus","volume":"54","author":"Yong","year":"2015","journal-title":"Australas J Dermatol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/DAD.0b013e3181c80cf9","article-title":"Grover disease: a reappraisal of histological diagnostic criteria in 120 cases","volume":"23","author":"Fernansez-Figueras","year":"2010","journal-title":"Am J Dermatopathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201701000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:12:15Z","timestamp":1694149935000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201701000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000587","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}